Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta

Journal of Bone and Mineral Research

Volumn 29, Issue 10, 2014, Pages 2297-2306

  Jacobsen, Christina M ^a,b   Barber, Lauren A ^a   Ayturk, Ugur M ^a,b   Roberts, Heather J ^a   Deal, Lauren E ^c   Schwartz, Marissa A ^a   Weis, MaryAnn ^d   Eyre, David ^d   Zurakowski, David ^a   Robling, Alexander G ^c   Warman, Matthew L ^a,b,e  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c INDIANA UNIVERSITY   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Anabolics; Cell Tissue signaling; Diseases and disorders of bone; Genetic animal models; Osteogenesis imperfecta; Paracrine pathways; Wnt Beta Catenin LRPS

Indexed keywords

COLLAGEN TYPE 1; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; MESSENGER RNA; MONOCLONAL ANTIBODY; SCLEROSTIN; COLLAGEN; GLYCOPROTEIN; SOST PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE FRAGILITY; BONE MASS; BONE STRENGTH; MALE; MOUSE; NONHUMAN; OSSIFICATION; OSTEOGENESIS IMPERFECTA; PROTEIN EXPRESSION; PROTEIN SECRETION; ALLELE; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE; BONE DEVELOPMENT; DISEASE MODEL; FEMALE; GENETICS; HUMAN; METABOLISM; MUTATION; PATHOLOGY; SIGNAL TRANSDUCTION;

ALLELES; ANIMALS; BONE AND BONES; COLLAGEN; DISEASE MODELS, ANIMAL; FEMALE; GLYCOPROTEINS; HUMANS; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-5; MALE; MICE; MUTATION; OSTEOGENESIS; OSTEOGENESIS IMPERFECTA; SIGNAL TRANSDUCTION;

EID: 84903547995     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2198     Document Type: Article

References (52)

1. Cundy T. Recent advances in osteogenesis imperfecta. Calcif Tissue Int. 2012 Jun;90(6):439-49.
2. Byers PH, Pyott SM. Recessively inherited forms of osteogenesis imperfecta. Annu Rev Genet. 2012;46:475-97.
3. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998 Oct 1;339(14):947-52.
4. Falk MJ, Heeger S, Lynch KA, et al. Intravenous bisphosphonate therapy in children with osteogenesis imperfecta. Pediatrics. 2003 Mar;111(3):573-8.
5. Alharbi M, Pinto G, Finidori G, et al. Pamidronate treatment of children with moderate-to-severe osteogenesis imperfecta: a note of caution. Horm Res. 2009 Jan;71(1):38-44.
6. Bradbury LA, Barlow S, Geoghegan F, et al. Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists. Osteoporos Int. 2012 Jan;23(1):285-94.
7. Phillipi CA, Remmington T, Steiner RD. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2008; (4):CD005088.
8. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010 Nov;25(11):2267-94.
9. Sellmeyer DE. Atypical fractures as a potential complication of long-term bisphosphonate therapy. JAMA. 2010 Oct 6;304(13):1480-4.
10. Gong Y, Slee RB, Fukai N, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001 Nov 16;107(4):513-23.
11. Little RD, Carulli JP, Del Mastro RG, et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet. 2002 Jan;70(1):11-9.
12. Boyden LM, Mao J, Belsky J, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 2002 May 16;346(20):1513-21.
13. Semenov MV, He X. LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST. J Biol Chem. 2006 Dec 15;281(50):38276-84.
14. Balemans W, Piters E, Cleiren E, et al. The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations. Calcif Tissue Int. 2008 Jun;82(6):445-53.
15. Ellies DL, Viviano B, McCarthy J, et al. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J Bone Miner Res. 2006 Nov;21(11):1738-49.
16. Cui Y, Niziolek PJ, MacDonald BT, et al. Lrp5 functions in bone to regulate bone mass. Nat Med. 2011 Jun;17(6):684-91.
17. Brunkow ME, Gardner JC, Van Ness J, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001 Mar;68(3):577-89.
18. Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the de ficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001 Mar 1;10(5):537-43.
19. Staehling-Hampton K, Proll S, Paeper BW, et al. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet. 2002 Jun 15;110(2):144-52.
20. Balemans W, Patel N, Ebeling M, et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet. 2002 Feb;39(2):91-7.
21. Agholme F, Li X, Isaksson H, Ke HZ, Aspenberg P. Sclerostin antibody treatment enhances metaphyseal bone healing in rats. J Bone Miner Res. 2010 Nov;25(11):2412-8.
22. Ominsky MS, Li C, Li X, et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res. 2011 May;26(5):1012-21.
23. Ominsky MS, Vlasseros F, Jolette J, et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res. 2010 May;25(5):948-59.
24. Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011 Jan;26(1):19-26.
25. Li X, Warmington KS, Niu QT, et al. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res. 2010 Dec; 25(12):2647-56.
26. Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009 Apr;24(4):578-88.
27. Daley E, Streeten EA, Sorkin JD, et al. Variable bone fragility associated with an Amish COL1A2 variant and a knock-in mouse model. J Bone Miner Res. 2010 Feb;25(2):247-61.
28. Truett GE, Heeger P, Mynatt RL, Truett AA, Walker JA, Warman ML. Preparation of PCR-quality mouse genomic DNA with hot sodium hydroxide and tris (HotSHOT). Biotechniques. 2000 Jul;29(1):52 54.
29. Sawakami K, Robling AG, Ai M, et al. The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment. J Biol Chem. 2006 Aug 18;281(33):23698-711.
30. Hanna SL, Sherman NE, Kinter MT, Goldberg JB. Comparison of proteins expressed by Pseudomonas aeruginosa strains representing initial and chronic isolates from a cystic fibrosis patient: an analysis by 2-D gel electrophoresis and capillary column liquid chromatography-tandem mass spectrometry. Microbiology. 2000 Oct;146(Pt 10):2495-508.
31. Eyre DR, Weis MA, Wu JJ. Advances in collagen cross-link analysis. Methods. 2008 May;45(1):65-74.
32. Ayturk UM, Jacobsen CM, Christodoulou DC, et al. An RNA-seq protocol to identify mRNA expression changes in mouse diaphyseal bone: applications in mice with bone property altering Lrp5 mutations. J Bone Miner Res. 2013 Oct;28(10):2081-93.
33. Grant GR, Farkas MH, Pizarro AD, et al. Comparative analysis of RNA-Seq alignment algorithms and the RNA-Seq unified mapper (RUM). Bioinformatics. 2011 Sep 15;27(18):2518-28.
34. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010 Jan 1;26(1):139-40.
35. Shapiro SS, Wilk WB. An analysis of variance test for normality. Biometrika. 1965;52:591-611.
36. Sokal RR. Biometry: the principles and practice of statistics in biological research. 3rd ed. New York: W. H. Freeman; 1995.
37. Sinder BP, Eddy MM, Ominsky MS, Caird MS, Marini JC, Kozloff KM. Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta. J Bone Miner Res. 2013 Jan;28(1):73-80.
38. Li X, Zhang Y, Kang H, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005 May 20;280(20):19883-7.
39. Semenov M, Tamai K, He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem. 2005 Jul 22;280(29):26770-5.
40. Holmen SL, Giambernardi TA, Zylstra CR, et al. Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6. J Bone Miner Res. 2004 Dec;19(12):2033-40.
41. Motyl KJ, Dick-de-Paula I, Maloney AE, et al. Trabecular bone loss after administration of the second-generation antipsychotic risperidone is independent of weight gain. Bone. 2012 Feb;50(2):490-8.
42. Shahnazari M, Wronski T, Chu V, et al. Early response of bone marrow osteoprogenitors to skeletal unloading and sclerostin antibody. Calcif Tissue Int. 2012 Jul;91(1):50-8.
43. Bogan R, Riddle RC, Li Z, et al. A mouse model for human osteogenesis imperfecta type VI. J Bone Miner Res. 2013 Jul;28(7):1531-6.
44. Vranka JA, Pokidysheva E, Hayashi L, et al. Prolyl 3-hydroxylase 1 null mice display abnormalities in fibrillar collagen-rich tissues such as tendons, skin, and bones. J Biol Chem. 2010 May 28;285(22):17253-62.
45. Morello R, Bertin TK, Chen Y, et al. CRTAP is required for prolyl 3-hydroxylation and mutations cause recessive osteogenesis imperfecta. Cell. 2006 Oct 20;127(2):291-304.
46. Lisse TS, Thiele F, Fuchs H, et al. ER stress-mediated apoptosis in a new mouse model of osteogenesis imperfecta. PLoS Genet. 2008 Feb;4(2):e7.
47. Aubin I, Adams CP, Opsahl S, et al. A deletion in the gene encoding sphingomyelin phosphodiesterase 3 (Smpd3) results in osteogenesis and dentinogenesis imperfecta in the mouse. Nat Genet. 2005 Aug;37(8):803-5.
48. Forlino A, Porter FD, Lee EJ, Westphal H, Marini JC. Use of the Cre/lox recombination system to develop a non-lethal knock-in murine model for osteogenesis imperfecta with an alpha1(I) G349C substitution. Variability in phenotype in BrtlIV mice. J Biol Chem. 1999 Dec 31;274(53):37923-31.
49. Chipman SD, Sweet HO, McBride DJ Jr, et al. Defective pro alpha 2(I) collagen synthesis in a recessive mutation in mice: a model of human osteogenesis imperfecta. Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1701-5.
50. Hartung S, Jaenisch R, Breindl M. Retrovirus insertion inactivates mouse alpha 1(I) collagen gene by blocking initiation of transcription. Nature. 1986 Mar 27-Apr 2;320(6060):365-7.
51. Lindahl K, Barnes AM, Fratzl-Zelman N, et al. COL1 C-propeptide cleavage site mutations cause high bone mass osteogenesis imperfecta. Hum Mutat. 2011 Jun;32(6):598-609.
52. Uveges TE, Kozloff KM, Ty JM, et al. Alendronate treatment of the brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation. J Bone Miner Res. 2009 May;24(5):849-59.